1 |
Qin LX, Tang ZY (2002). The prognostic significance of clinical and pathological features in hepatocellular carcinoma. World J Gastroenterol, 8, 193-9.
|
2 |
Stotz M, Gerger A, Eisner F, et al (2013). Increased neutrophillymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer, 109, 416-21.
DOI
ScienceOn
|
3 |
Karaman M, Balta S, Ay SA, et al (2013). The comparative effects of valsartan and amlodipine on vWf Levels and N/L ratio in patients with newly diagnosed hypertension. Clin Exp Hypertens, 35, 516-22.
DOI
ScienceOn
|
4 |
Mulcahy MF (2005). Management of hepatocellular cancer. Curr Treat Options Oncol, 6, 423-35.
DOI
ScienceOn
|
5 |
Zheng YB, Zhao W, Liu B, et al (2013). The blood neutrophil-tolymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib. Asian Pac J Cancer Prev, 14, 5527-31.
과학기술학회마을
DOI
ScienceOn
|
6 |
Balta S, Cakar M, Demirkol S, Arslan Z, Akhan M (2013). Higher neutrophil to lymhocyte ratio in patients with metabolic syndrome. Clin Appl Thromb Hemost, 19, 579.
DOI
ScienceOn
|
7 |
Song T, Zhang W, Wu Q, Kong D, Ma W (2011). A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors. Eur J Gastroenterol Hepatol, 23, 1233-8.
DOI
|